Stay updated on Phase II Nivolumab and Ramucirumab for Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Phase II Nivolumab and Ramucirumab for Mesothelioma Clinical Trial page.

Latest updates to the Phase II Nivolumab and Ramucirumab for Mesothelioma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows revision v3.4.2, replacing v3.4.1. This is a maintenance update and does not alter the study details, eligibility, or results.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page now shows revision v3.4.1 instead of v3.4.0, indicating a minor metadata update with no impact on the study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a new Locations section listing Florida, Maryland, Michigan, and Minnesota. Updated the page revision from v3.3.2 to v3.3.3 and removed the old location blocks.SummaryDifference0.5%

- Check91 days agoChange DetectedAdded an auto-generated PubMed note and updated the page revision to v3.3.2. Removed the older PubMed note referencing v3.2.0.SummaryDifference0.1%

- Check99 days agoChange DetectedRemoval of the funding/operational status banner that previously informed users about data timeliness and potential delays. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Phase II Nivolumab and Ramucirumab for Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Nivolumab and Ramucirumab for Mesothelioma Clinical Trial page.